Saltar al contenido
Merck

Saltar a

F0806

Factor IX human

aqueous glycerol solution, ≥145 units/mg protein

Sinónimos:

Christmas factor, Plasma thromboplastin component

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas
Tamaño de envaseSKUDisponibilidadPrecio
100 μg
Comprobar disponibilidad del carrito
MXP 6,670.00

Acerca de este artículo

Número CAS:
UNSPSC Code:
12352202
NACRES:
NA.61
MDL number:
Form:
aqueous glycerol solution
Biological source:
human
Mol wt:
55 kDa

MXP 6,670.00


Comprobar disponibilidad del carrito

Solicite una orden a granel
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle


biological source

human

Quality Level

form

aqueous glycerol solution

specific activity

≥145 units/mg protein

mol wt

55 kDa

technique(s)

ligand binding assay: suitable

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... F9(2158)

General description

Factor IX is a 55 kDa single chain vitamin K-dependent plasma zymogen which plays a key role in the intrinsic and extrinsic blood coagulation systems.

Application

Factor IX is plasma zymogen key to blood coagulation systems. It has been used in studies of portal vein thrombosis (PVT) in hepatocellular carcinoma (HCC). It has been found that abnormalities in factor IX contribute to PVT in HCC patients. Additionally, it has been used in studies of changes in the coagulation system in patients with inflammatory bowel disease (IBD).

Physical form

Aqueous solution containing 50% (v/v) glycerol

Other Notes

One unit is equivalent to the Factor IX activity in 1.0 mL of normal human plasma at pH 7.4 at 37 °C.
View this factors role in the Coagulation Cascade

Disclaimer

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Comparar elementos similares

Ver comparación completa

Mostrar Diferencias

1 of 1

Este artículo
F0681SRP6185F0931
technique(s)

ligand binding assay: suitable

technique(s)

ligand binding assay: suitable

technique(s)

-

technique(s)

ligand binding assay: suitable

biological source

human

biological source

human

biological source

human plasma

biological source

human

mol wt

55 kDa

mol wt

-

mol wt

heavy chain 94.0 kDa, light chain 74 kDa

mol wt

168 kDa

form

aqueous glycerol solution

form

aqueous glycerol solution

form

liquid

form

solution

specific activity

≥145 units/mg protein

specific activity

≥25 units/mg protein

specific activity

-

specific activity

≥1500 units/mg protein

Gene Information

human ... F9(2158)

Gene Information

human ... F5(2153)

Gene Information

human ... F5(2153)

Gene Information

human ... F5(2153)


Clase de almacenamiento

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos


Contenido relacionado

Instructions


Brian R Branchford et al.
Current opinion in pediatrics, 25(1), 23-30 (2013-01-01)
Disorders of hemostasis such as hemophilia, von Willebrand disease (VWD), and other clotting protein deficiencies lead to significant morbidity in the pediatric population. Because of the limitations of current treatment options, novel therapies are being developed, many of which are
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Alkim H., et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2011)
Cassandra L Pegg et al.
Glycoconjugate journal, 37(4), 471-483 (2020-05-08)
Human Factor IX is a highly post-translationally modified protein that is an important clotting factor in the blood coagulation cascade. Functional deficiencies in Factor IX result in the bleeding disorder haemophilia B, which is treated with plasma-derived or recombinant Factor



Número de artículo de comercio global

SKUGTIN
F0806-100UG04061838031044

Questions

Reviews

No rating value

Active Filters